ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter, 2019

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2019 and provided an update on the Company's recent developments.

R&D investments of $8.9 million for the 9 months ended September 30, 2019 have permitted Oryzon to significantly advance its clinical portfolio.

Click here to see the full Press Release